TrialGynecologic oncology2012

A phase II study single agent of aflibercept (VEGF Trap) in patients with recurrent or metastatic gynecologic carcinosarcomas and uterine leiomyosarcoma. A trial of the Princess Margaret Hospital, Chicago and California Cancer Phase II Consortia.

H J Mackay et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.